Drug data last refreshed 13h ago · AI intelligence enriched 16h ago
Morphine sulfate is an opioid analgesic indicated for moderate to severe pain management. Administered as an oral solution, it works by binding to opioid receptors in the central nervous system to reduce pain perception. This product is a mature, off-patent formulation widely used across acute and chronic pain settings.
As an approaching LOE product with moderate competitive pressure (60%), commercial teams face defensive positioning challenges with limited growth trajectory and potential workforce rationalization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Working on morphine sulfate offers limited career advancement due to its mature, commoditized market position and approaching loss of exclusivity. Roles focus on defensive commercial strategy, cost management, and operational efficiency rather than innovation or market expansion.
Worked on MORPHINE SULFATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo